Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-03-21
2010-10-05
Shiao, Rei-tsang (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S566000
Reexamination Certificate
active
07807709
ABSTRACT:
The invention relates to the use of (3,4-di-, 3,3,4-tri, 3,4,4-tri- or 3,3,4,4-tetra-)substituted pyrrolidine compounds for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; compounds that are part of a subclass of these substituted pyrrolidine compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; new compounds that are part of a subclass of these substituted pyrrolidine compounds; pharmaceutical formulations comprising said substituted pyrrolidine compounds, and/or a method of treatment comprising administering said substituted pyrrolidine compounds, a method for the manufacture especially of said new substituted pyrrolidine compounds, as well as novel intermediates, starting materials and/or partial steps for their synthesis.
REFERENCES:
patent: 7582782 (2009-09-01), Baeschlin et al.
patent: 2004/0019137 (2004-01-01), Hebrault
patent: 2004/0077551 (2004-04-01), Campbell et al.
patent: 2009/0312304 (2009-12-01), Breitenstein et al.
patent: 2010/0029647 (2010-02-01), Masuya et al.
patent: 1583724 (2005-02-01), None
patent: 0242789 (1987-10-01), None
patent: WO 93/12108 (1993-06-01), None
patent: WO 95/09858 (1995-04-01), None
patent: WO 99/09984 (1999-03-01), None
patent: WO 99/65867 (1999-12-01), None
patent: WO 00/26211 (2000-05-01), None
patent: 0051609 (2000-09-01), None
patent: WO 00/51607 (2000-09-01), None
patent: WO 00/51608 (2000-09-01), None
patent: WO 00/51610 (2000-09-01), None
patent: WO 01/70673 (2001-09-01), None
patent: WO 02/34716 (2002-05-01), None
patent: WO 03/024899 (2003-03-01), None
patent: WO 03/031443 (2003-04-01), None
patent: WO 03/032962 (2003-04-01), None
patent: 03/099767 (2003-12-01), None
patent: WO 04/004665 (2004-01-01), None
patent: 2005/070870 (2005-08-01), None
patent: 2005/070871 (2005-08-01), None
patent: 2005/070877 (2005-08-01), None
patent: 2005/090304 (2005-09-01), None
patent: 2005/090305 (2005-09-01), None
patent: 2006/061426 (2006-06-01), None
patent: 2006/095020 (2006-09-01), None
Specker et al., 2006, CAS: 145: 210822.
Taylor G M et al: “On the Ritter Reaction of Cyclic Hydroxyamines: Synthesis of Conformationally-Restricted Reduced Amide Dipeptide Isoteres” Tetrahedron Letters, vol. 37, No. 8, Feb. 19, 1996, pp. 1297-1300. The whole document.
N.D.L. Fischer and N.K. Hollenberg: “Is there a future for renin inhibitors?” Expert Opinion on Investigational Drugs, vol. 10, No. 3, 2001, pp. 417-426. The whole document.
Wood J M et al: “Inhibitors of renin as potential therapeutic agents” Journal of Enzyme Inhibition, vol. 1, No. 3, 1987, pp. 169-185. The whole document.
Wood Jeanette M et al: “Structure-based design of aliskiren, a novel orally effective renin inhibitor.” Biochemical and Biophysical Research Communications, vol. 308, No. 4, Sep. 5, 2003, pp. 698-705. The whole document.
Specker et al.; Angew Chem Int Ed (2005); 44; 3140.
Fevig et al.; Bioorg & Med Chem Letters (1996); 6(3); 295.
Thomas et al.; Bioorg & Med Chem Letters (1998); 8; 2885.
Bucsh et al.; J Med Chem (1993); 36(26); 4139.
Co-pending U.S. Appl. No. 11/721,457 filed Oct. 13, 2009 owned by Novartis AG.
Co-pending U.S. Appl. No. 11/908,182 filed Sep. 10, 2007 owned by Novartis AG.
Maibaum, et al., “Renin inhibitors as novel treatment for cardiovascular diseases” Expert opinion on therapeutic patents, vol. 13, No. 5, 2003, 589-603.
Ehrhardt Claus
Irie Osamu
Lorthiois Edwige Liliane
Maibaum Juergen Klaus
Ostermann Nils
Cross Sophie Binet
Novartis AG
Shiao Rei-tsang
LandOfFree
Organic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Organic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Organic compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4220871